Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer.

We compared the groups of patients diagnosed with BM at NSCLC diagnosis, patients who previously received systemic chemotherapy (CT) for their underlying NSCLC disease (labeled “after CT”), and patients who received any combination of immune checkpoint blockade (ICB) and chemotherapeutics prior to their BM diagnosis (labeled “after IT”) and saw a slight trend toward a survival benefit of patients that previously received a combination of CT and ICB [ Figure 2I , median 9.80 ± 1.87 vs. 22.73 ± 7.09 vs. 10.87 ± 2.34 months, respectively, p = 0.285, log-rank (Mantel–Cox) test], which we will follow up in further studies.

also in 4,078 other papers